Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 2

Sponsor Class

NETWORK 3NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Carcinoma, Renal Cell 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Colony-Stimulating Factors × Clear all
NCT01265901 2017-10-12

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Immatics Biotechnologies GmbH

Phase 3 Completed
339 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01368276 2015-12-18

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

BioVex Limited

Phase 3 Completed
31 enrolled 11 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡